Silence Therapeutics SEC filings: 8-K
Filter: All · 8-K · 10-Q · 10-K · Form 4
Entry into a material definitive agreement · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedSilence Therapeutics agrees to be acquired by Merck KGaA for $20.00 per ADS in cash, about $1.3 billion equity value
Entry into a material definitive agreement · Other events · Financial statements and exhibits
Regulation FD disclosure · Other events · Financial statements and exhibits
Results of operations and financial condition · Financial statements and exhibits